Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2052 ARTÍCULOS , VIENDO DEL 1561 AL 1575

Research Progress on Mechanism of Neuroprotective Roles of Apelin-13 in Prevention and Treatment of Alzheimer's Disease

Wan T, Fu M, Jiang Y, Jiang W, Li P, Zhou S.

Neurochem Res. 2022 Feb;47(2):205-217. doi: 10.1007/s11064-021-03448-1. Epub 2021 Sep 13.

A critical appraisal of tau-targeting therapies for primary and secondary tauopathies

Imbimbo BP, Ippati S, Watling M, Balducci C.

Alzheimers Dement. 2022 May;18(5):1008-1037. doi: 10.1002/alz.12453. Epub 2021 Sep 17.

Ketones: potential to achieve brain energy rescue and sustain cognitive health during ageing

Myette-Côté É, Soto-Mota A, Cunnane SC.

Br J Nutr. 2022 Aug 14;128(3):407-423. doi: 10.1017/S0007114521003883. Epub 2021 Sep 28.

Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria

Franzen S, Smith JE, van den Berg E, Rivera Mindt M, van Bruchem-Visser RL, Abner EL, Schneider LS, Prins ND, Babulal GM, Papma JM.

Alzheimers Dement. 2022 Apr;18(4):810-823. doi: 10.1002/alz.12433. Epub 2021 Sep 30.

Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report

Jicha GA, Abner EL, Arnold SE, Carrillo MC, Dodge HH, Edland SD, Fargo KN, Feldman HH, Goldstein LB, Hendrix J, Peters R, Robillard JM, Schneider LS, Titiner JR, Weber CJ; Clinical Trial Advancement & Methodology Professional Interest Area of the International Society to Advance Alzheimer's Research and Treatment (ISTAART).

Alzheimers Dement. 2022 Jun;18(6):1109-1118. doi: 10.1002/alz.12461. Epub 2021 Sep 29.

Network activity changes in the pathophysiology of Alzheimer's disease: the role of aging and early entorhinal cortex dysfunction

Setti SE, Reed MN.

Metab Brain Dis. 2022 Feb;37(2):289-298. doi: 10.1007/s11011-021-00848-8. Epub 2021 Sep 30.

Accelerated Approval of Aducanumab: Where Do We Stand Now?

Barenholtz Levy H.

Ann Pharmacother. 2022 Jun;56(6):736-739. doi: 10.1177/10600280211050405. Epub 2021 Oct 1.

Polygenic variants related to familial hypobetalipoproteinemia in a patient with Alzheimer's disease homozygotic for the APOE ε2 allele presenting multiple cortical superficial siderosis and recurrent lobar hemorrhages

Ikeda M, Okamoto K, Suzuki K, Amari M, Takai E, Takatama M, Yokoo H, Ishibashi S, Ikeda Y.

Neurogenetics. 2022 Jan;23(1):69-71. doi: 10.1007/s10048-021-00672-3. Epub 2021 Oct 2.

Intracellular ion changes induced by the exposure to beta-amyloid can be explained by the formation of channels in the lysosomal membranes

Zaretsky DV, Zaretskaia MV.

Biochim Biophys Acta Mol Cell Res. 2022 Jan;1869(1):119145. doi: 10.1016/j.bbamcr.2021.119145. Epub 2021 Oct 2.

Humanin and Alzheimer's disease: The beginning of a new field

Niikura T.

Biochim Biophys Acta Gen Subj. 2022 Jan;1866(1):130024. doi: 10.1016/j.bbagen.2021.130024. Epub 2021 Oct 7.

Interpretable artificial intelligence and exascale molecular dynamics simulations to reveal kinetics: Applications to Alzheimer's disease

Martin W, Sheynkman G, Lightstone FC, Nussinov R, Cheng F.

Curr Opin Struct Biol. 2022 Feb;72:103-113. doi: 10.1016/j.sbi.2021.09.001. Epub 2021 Oct 7.

Nectin-2 in general and in the brain

Mizutani K, Miyata M, Shiotani H, Kameyama T, Takai Y.

Mol Cell Biochem. 2022 Jan;477(1):167-180. doi: 10.1007/s11010-021-04241-y. Epub 2021 Oct 11.

PM2.5 exposure in association with AD-related neuropathology and cognitive outcomes

Thiankhaw K, Chattipakorn N, Chattipakorn SC.

Environ Pollut. 2022 Jan 1;292(Pt A):118320. doi: 10.1016/j.envpol.2021.118320. Epub 2021 Oct 8.

The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer's disease: a randomized, triple-blind, placebo-controlled trial

Louzada LL, Machado FV, Quintas JL, Ribeiro GA, Silva MV, Mendonça-Silva DL, Gonçalves BSB, Nóbrega OT, Camargos EF.

Neuropsychopharmacology. 2022 Jan;47(2):570-579. doi: 10.1038/s41386-021-01191-3. Epub 2021 Oct 11.

Of education and public policy: Aducanumab

Lundebjerg NE, Hollmann PA, Supiano MA.

J Am Geriatr Soc. 2022 Jan;70(1):81-84. doi: 10.1111/jgs.17523. Epub 2021 Nov 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias